| Literature DB >> 24203976 |
Alexandros Onoufriadis1, Amelia Shoemark, Mustafa M Munye, Chela T James, Miriam Schmidts, Mitali Patel, Elisabeth M Rosser, Chiara Bacchelli, Philip L Beales, Peter J Scambler, Stephen L Hart, Jeannette E Danke-Roelse, John J Sloper, Sarah Hull, Claire Hogg, Richard D Emes, Gerard Pals, Anthony T Moore, Eddie M K Chung, Hannah M Mitchison.
Abstract
BACKGROUND: Primary ciliary dyskinesia (PCD) is a rare, genetically heterogeneous ciliopathy disorder affecting cilia and sperm motility. A range of ultrastructural defects of the axoneme underlie the disease, which is characterised by chronic respiratory symptoms and obstructive lung disease, infertility and body axis laterality defects. We applied a next-generation sequencing approach to identify the gene responsible for this phenotype in two consanguineous families. METHODS ANDEntities:
Keywords: Clinical Genetics; Developmental; Genetics; Molecular Genetics; Other Respiratory Medicine
Mesh:
Substances:
Year: 2013 PMID: 24203976 PMCID: PMC3888613 DOI: 10.1136/jmedgenet-2013-101938
Source DB: PubMed Journal: J Med Genet ISSN: 0022-2593 Impact factor: 6.318
Figure 1ARMC4 mutations, protein analysis and upregulation during ciliogenesis. (A) Pedigree structure and segregation analysis of the two primary ciliary dyskinesia (PCD) families in whom ARMC4 mutations were identified. Asterisk indicates situs inversus, hash indicates dextrocardia. (B) Model of ARMC4 protein with ARM repeats in purple (residues 482–523, 524–564, 565–620, 621–661, 662–702, 703–744, 745–785, 786–826, 868–910, 911–951, 952–992, 993–1033) and low complexity regions in yellow (residues 73–84, 174–189, 424–438). The predicted ARM repeat superhelix is shown below the linear representation, with dark blue indicating the region lost by the Ser892* mutation, and dark plus light blue the region lost by the Glu658* mutation. (C) STRING predicted protein interactions for ARMC4. (D) ARMC4 expression is induced upon ciliogenesis. A marked increase in ARMC4 mRNA levels and the control PCD-associated gene DNAI1 was observed in ciliated normal human bronchial epithelial cells compared to non-ciliated cells. Normal human bronchial epithelial cells (NHBE; Lonza) were cultured submerged on collagen-coated plates with Bronchial Epithelial Growth Media (Lonza), seeded onto transwells and cultured at an air–liquid interface for 28 days essentially as previously described,26 then analysed by qPCR performed with TaqMan primer probes and PCR products detected with an Applied Biosystems (ABI) Prism 7000 Sequence Detection System (Applied Biosystems). The fold difference in gene expression between the two was assessed normalised to GAPDH as an endogenous control, using the delta-delta Ct method. The TaqMan probes were DNAI1, Hs00201755_m1; ARMC4, Hs00216318_m1; GAPDH, Hs02758991_g1. Data are plotted as the mean, and error bars represent the SEM of triplicate repeats experiments.
Figure 2ARMC4 mutations result in outer dynein arms defects. (A) Transmission electron microscopy of nasal respiratory epithelial cell cilia demonstrates loss of the outer dynein arms (indicated by the arrows) in primary ciliary dyskinesia (PCD) patients carrying ARMC4 mutations compared to controls. Scale bar, 100 nm. A close-up of the peripheral outer doublet microtubules in the PCD-221 II:1 patient is indicated in a red box, to highlight the loss of the outer arms with retention of inner arms. (B) In healthy individuals, both ARMC4 and DNAH5 are localised along the length of the axoneme of respiratory epithelial cells. In individual PCD-221 II:1, ARMC4 is markedly reduced along the full length of the axoneme and DNAH5 is present only in the proximal portion of the cilia closest to the basal body, but significantly reduced at the distal end of the cilia. Cilia axonemal immunostaining was performed using antisera against ARMC4 (Sigma HPA037829) and the outer dynein arm protein DNAH5 (Sigma HPA037470) (both green). Axoneme-specific anti-acetylated-α-tubulin antibody (Sigma) was used as a control to stain the entire axoneme (red), and (DAPI is 4',6-diamidino-2-phenylindole) (Invitrogen) was used to stain DNA (blue). Scale bars, 10 μm.